Custom Synthesis drives earnings

Company
27 May 2024
5 Min read 
  • Divis Laboratories' financial performance and valuation changes are highlighted.
  •  The company's revenue and EBITDA margins improved in 4QFY24.
  •  The company's focus on Custom Synthesis and API segments is driving growth.
  •  The management expects a 27% earnings CAGR over FY24-26.
  •  The company's valuations capture the earnings upside, leading to a neutral rating.
  •  Divis Laboratories is making strides in both the CS and API segments.
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority

Click here to see your activities